USPTO 2015–2025 USPTO PatentsView US Corporation

Sirna Therapeutics, Inc.

USPTO PatentsView assignee record — 72 granted patents across 11 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).

72
Total patents granted
11
CPC technology areas
19.4
Avg claims per patent
-64%
5-year filing velocity

Portfolio overview

Sirna Therapeutics, Inc. has been granted 72 US utility patents between 2015 and 2025, placing Sirna Therapeutics, Inc. at rank #4,843 across all assignees tracked by PlainPatent. This portfolio spans 11 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.4 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Sirna Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 39.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 19 grants, compared with 53 in the 2015–2019 window — a -64% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Sirna Therapeutics, Inc.'s 19.4 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 11 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Sirna Therapeutics, Inc. against peers pursuing similar technology classes.

How does Sirna compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Sirna holds 72 patents — placing it at rank #4,843 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

USPTO utility patent grants by year · 2015–2025

05101520 2015201620172018201920202021202220242025 1
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Sirna Therapeutics, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 9 12.5%
2016 12 16.7%
2017 16 22.2%
2018 9 12.5%
2019 7 9.7%
2020 10 13.9%
2021 3 4.2%
2022 2 2.8%
2024 3 4.2%
2025 1 1.4%

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Declining

Where it ranks

Overall rank by patents

#4,843

Across all tracked assignees

Innovation Score

39.9 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Sirna Therapeutics, Inc. hold?
Sirna Therapeutics, Inc. holds 72 US granted patents filed between 2015 and 2025, spanning 11 technology areas.
What is Sirna Therapeutics, Inc.'s Innovation Score?
Sirna Therapeutics, Inc. has an Innovation Score of 39.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Sirna Therapeutics, Inc. focus on?
Sirna Therapeutics, Inc.'s top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 70 patents. The company has filed patents in 11 CPC subclasses total.
Is Sirna Therapeutics, Inc.'s patent filing rate increasing or decreasing?
Sirna Therapeutics, Inc.'s recent filing velocity is -64% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Sirna Therapeutics, Inc.'s patents?
Sirna Therapeutics, Inc.'s patents average 19.4 claims each. This falls within the standard range, providing solid legal coverage.
How is the Sirna Therapeutics, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope